Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells
Authors:
- Harald HartwegerHHHarald Hartweger
- Andrew T. McGuireAMAndrew T. McGuire
- Marcel HorningMHMarcel Horning
- Justin J. TaylorJTJustin J. Taylor
- Pia DosenovicPDPia Dosenovic
- Daniel YostDYDaniel Yost
- Anna GazumyanAGAnna Gazumyan
- Michael S. SeamanMSMichael S. Seaman
- Leonidas StamatatosLSLeonidas Stamatatos
- Mila JankovicMJMila Jankovic
- Michel C. NussenzweigMNMichel C. Nussenzweig
Preprint
- 26 January 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 530832
Abstract
A small number of HIV-1 infected individuals develop broadly neutralizing-antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1 - 3 years after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be editedin vitrousing CRISPR/Cas9 to express mature bNAbs from the endogenousIghlocus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization.One-sentence summary: B cells edited by CRISPR/Cas9 to produce antibodies participate in humoral immune reactions and secrete neutralizing serum titers of anti-HIV bNAbs.Keywords
All Related Versions
- Published version: Journal of Experimental Medicine, 216 (6), 1301.
This publication has 45 references indexed in Scilit:
- Towards the Generation of B-Cell Receptor Retrogenic MicePLOS ONE, 2014
- Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaquesJournal of Experimental Medicine, 2014
- Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodiesProceedings of the National Academy of Sciences, 2012
- Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunizationJournal of Experimental Medicine, 2012
- Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene AssaysCurrent Protocols in Immunology, 2004
- Survival of Resting Mature B Lymphocytes Depends on BCR Signaling via the Igα/β HeterodimerCell, 2004
- Role of antigen receptor affinity in T cell–independent antibody responses in vivoNature Immunology, 2002
- Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In VitroJournal of Virology, 2001
- Allelic Exclusion in Transgenic Mice That Express the Membrane form of Immunoglobulin μScience, 1987
- CELLULAR LOCALIZATION OF IMMUNOGLOBULINS WITH DIFFERENT ALLOTYPIC SPECIFICITIES IN RABBIT LYMPHOID TISSUESJournal of Experimental Medicine, 1965